title: Management of metastatic malignant thymoma with advanced radiation and chemotherapy techniques: report of a rare case.
abstract: Malignant thymomas are rare epithelial neoplasms of the anterior superior mediastinum that are typically invasive in nature and have a higher risk of relapse that may ultimately lead to death. Here we report a case of an advanced malignant thymoma that was successfully treated with neoadjuvant chemotherapy followed by surgical resection and subsequently with advanced and novel radiation therapy techniques. A 65-year-old male was diagnosed with a stage IV malignant thymoma with multiple metastatic lesions involving the left peripheral lung and pericardium. Initial neoadjuvant chemotherapy with a cisplatin-based regimen resulted in a partial response allowing the inoperable tumor to become operable. Following surgical resection of the residual disease, the tumor recurred within a year. The patient then underwent a course of targeted three-dimensional intensity modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT). Five years after radiation therapy, the localized soft tissue thickening at the left upper lung anterior pleural space had resolved. Seven years after radiation therapy the tumor mass had completely resolved. No recurrences were seen and the patient is well even 8 years after IMRT/IGRT with a favorable outcome. Chemotherapy with targeted three-dimensional IMRT/IGRT should be considered the primary modality for the management of advanced malignant thymoma patients.
authors.affiliation: University Cancer and Diagnostic Centers, 12811 Beamer Road, Houston, TX, 77089, USA. mmmeead@aol.com.
authors.forename: Mark A
authors.initials: MA
authors.lastname: D'Andrea
authors.affiliation: University Cancer and Diagnostic Centers, 12811 Beamer Road, Houston, TX, 77089, USA. kreddy_usa@yahoo.com.
authors.forename: G Kesava
authors.initials: GK
authors.lastname: Reddy
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D019468:Disease Management; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy*; D008297:Male; D010496:Pericardium / Q000473:pathology*; D011379:Prognosis; D013945:Thymoma / Q000473:pathology / Q000628:therapy*; D013953:Thymus Neoplasms / Q000473:pathology / Q000628:therapy*